Elizabeth Kovacs
Concepts (559)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burns | 61 | 2025 | 325 | 17.480 |
Why?
| | Ethanol | 54 | 2025 | 608 | 8.700 |
Why?
| | Alcoholic Intoxication | 15 | 2023 | 68 | 5.650 |
Why?
| | Alcohol Drinking | 25 | 2025 | 821 | 4.850 |
Why?
| | Pneumonia | 14 | 2025 | 640 | 4.720 |
Why?
| | Inflammation | 32 | 2025 | 2836 | 3.800 |
Why?
| | Aging | 25 | 2025 | 1864 | 3.480 |
Why?
| | Alcoholism | 22 | 2024 | 806 | 3.120 |
Why?
| | Gastrointestinal Microbiome | 9 | 2025 | 698 | 2.970 |
Why?
| | Lung Transplantation | 15 | 2019 | 308 | 2.650 |
Why?
| | Immunity, Innate | 12 | 2017 | 827 | 2.530 |
Why?
| | Interleukin-6 | 17 | 2025 | 778 | 2.490 |
Why?
| | Cytokines | 20 | 2025 | 2090 | 2.280 |
Why?
| | Lung | 25 | 2025 | 4067 | 2.130 |
Why?
| | Feces | 4 | 2025 | 480 | 2.120 |
Why?
| | Macrophages, Alveolar | 9 | 2022 | 392 | 2.100 |
Why?
| | Neutrophils | 16 | 2022 | 1236 | 2.070 |
Why?
| | Liver Diseases | 5 | 2021 | 311 | 1.970 |
Why?
| | Dysbiosis | 5 | 2025 | 181 | 1.960 |
Why?
| | Mice | 67 | 2025 | 17774 | 1.930 |
Why?
| | Burns, Inhalation | 5 | 2020 | 9 | 1.930 |
Why?
| | Intestines | 4 | 2022 | 359 | 1.900 |
Why?
| | Binge Drinking | 8 | 2023 | 42 | 1.870 |
Why?
| | Animals | 96 | 2025 | 36862 | 1.840 |
Why?
| | Wound Healing | 11 | 2015 | 329 | 1.790 |
Why?
| | Mice, Inbred C57BL | 36 | 2025 | 5753 | 1.790 |
Why?
| | Macrophages | 13 | 2016 | 1544 | 1.710 |
Why?
| | Glycerophospholipids | 6 | 2025 | 34 | 1.700 |
Why?
| | Gastroesophageal Reflux | 10 | 2014 | 234 | 1.700 |
Why?
| | Bronchoalveolar Lavage Fluid | 15 | 2018 | 654 | 1.630 |
Why?
| | Lung Diseases | 9 | 2018 | 769 | 1.540 |
Why?
| | Age Factors | 17 | 2025 | 3297 | 1.520 |
Why?
| | Phagocytosis | 7 | 2016 | 379 | 1.350 |
Why?
| | Smoke Inhalation Injury | 6 | 2013 | 28 | 1.340 |
Why?
| | Neutrophil Infiltration | 8 | 2016 | 107 | 1.300 |
Why?
| | Disease Models, Animal | 22 | 2025 | 4284 | 1.260 |
Why?
| | Respiratory Aspiration | 4 | 2013 | 31 | 1.220 |
Why?
| | Bacterial Translocation | 6 | 2016 | 43 | 1.210 |
Why?
| | Public Opinion | 4 | 2023 | 66 | 1.190 |
Why?
| | Pseudomonas Infections | 4 | 2016 | 224 | 1.130 |
Why?
| | Central Nervous System Depressants | 3 | 2015 | 85 | 1.100 |
Why?
| | Macrophage Activation | 6 | 2019 | 201 | 1.090 |
Why?
| | Antimicrobial Cationic Peptides | 2 | 2025 | 81 | 1.070 |
Why?
| | Immune System | 5 | 2017 | 177 | 1.010 |
Why?
| | Bronchiolitis Obliterans | 6 | 2014 | 69 | 0.990 |
Why?
| | Male | 80 | 2025 | 67560 | 0.970 |
Why?
| | Calgranulin A | 1 | 2025 | 11 | 0.970 |
Why?
| | Radiation Injuries, Experimental | 3 | 2013 | 22 | 0.940 |
Why?
| | Liver | 10 | 2025 | 1941 | 0.930 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2025 | 70 | 0.920 |
Why?
| | Wound Infection | 2 | 2016 | 33 | 0.920 |
Why?
| | Pneumonia, Bacterial | 2 | 2016 | 117 | 0.870 |
Why?
| | Skin | 6 | 2016 | 751 | 0.830 |
Why?
| | Mice, Inbred BALB C | 12 | 2020 | 1269 | 0.820 |
Why?
| | Humans | 101 | 2025 | 137294 | 0.810 |
Why?
| | Postoperative Complications | 6 | 2018 | 2658 | 0.800 |
Why?
| | Chemokines | 8 | 2023 | 228 | 0.780 |
Why?
| | Radiation Injuries | 2 | 2016 | 146 | 0.770 |
Why?
| | Biomarkers | 19 | 2024 | 4164 | 0.750 |
Why?
| | Biomedical Research | 4 | 2018 | 693 | 0.750 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2022 | 48 | 0.740 |
Why?
| | Delirium | 1 | 2023 | 89 | 0.730 |
Why?
| | Tight Junctions | 1 | 2021 | 77 | 0.720 |
Why?
| | Signal Transduction | 14 | 2022 | 5078 | 0.720 |
Why?
| | Wounds and Injuries | 4 | 2015 | 756 | 0.710 |
Why?
| | Immunity, Cellular | 5 | 2018 | 268 | 0.700 |
Why?
| | Pneumococcal Infections | 1 | 2022 | 115 | 0.700 |
Why?
| | Female | 62 | 2025 | 73052 | 0.690 |
Why?
| | Astrocytes | 1 | 2022 | 210 | 0.680 |
Why?
| | Leukocytes | 3 | 2011 | 312 | 0.660 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2020 | 16 | 0.660 |
Why?
| | Estrogens | 2 | 2016 | 368 | 0.650 |
Why?
| | von Willebrand Factor | 1 | 2019 | 81 | 0.630 |
Why?
| | Allergy and Immunology | 2 | 2017 | 43 | 0.620 |
Why?
| | Intestinal Mucosa | 3 | 2021 | 622 | 0.610 |
Why?
| | Gastrointestinal Tract | 2 | 2020 | 195 | 0.600 |
Why?
| | Hepatitis, Alcoholic | 1 | 2018 | 13 | 0.600 |
Why?
| | Fatty Liver | 3 | 2017 | 243 | 0.590 |
Why?
| | Pseudomonas aeruginosa | 5 | 2014 | 351 | 0.590 |
Why?
| | Immunosenescence | 2 | 2017 | 4 | 0.590 |
Why?
| | Epigenesis, Genetic | 4 | 2022 | 659 | 0.580 |
Why?
| | Pepsin A | 3 | 2014 | 19 | 0.580 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2018 | 52 | 0.580 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2022 | 1242 | 0.580 |
Why?
| | Flow Cytometry | 6 | 2018 | 1184 | 0.580 |
Why?
| | Immunity | 3 | 2025 | 144 | 0.570 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 115 | 0.540 |
Why?
| | Sepsis | 5 | 2023 | 615 | 0.520 |
Why?
| | Chemokine CXCL1 | 3 | 2025 | 76 | 0.520 |
Why?
| | Histone Deacetylase 1 | 1 | 2016 | 25 | 0.520 |
Why?
| | Kupffer Cells | 1 | 2016 | 50 | 0.520 |
Why?
| | Aged | 24 | 2024 | 23851 | 0.510 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2023 | 607 | 0.510 |
Why?
| | Spleen | 5 | 2011 | 514 | 0.510 |
Why?
| | Tissue Donors | 3 | 2018 | 417 | 0.510 |
Why?
| | Myosin-Light-Chain Kinase | 2 | 2014 | 20 | 0.510 |
Why?
| | Length of Stay | 3 | 2019 | 1218 | 0.500 |
Why?
| | Pulmonary Edema | 1 | 2016 | 107 | 0.500 |
Why?
| | Inflammation Mediators | 6 | 2015 | 514 | 0.500 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2013 | 74 | 0.490 |
Why?
| | Laparoscopy | 5 | 2014 | 464 | 0.490 |
Why?
| | Middle Aged | 30 | 2024 | 33310 | 0.480 |
Why?
| | Adaptive Immunity | 2 | 2016 | 165 | 0.480 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 283 | 0.480 |
Why?
| | Intestine, Small | 2 | 2016 | 156 | 0.480 |
Why?
| | Microbiota | 1 | 2023 | 761 | 0.470 |
Why?
| | Bradykinin B2 Receptor Antagonists | 1 | 2015 | 1 | 0.470 |
Why?
| | Bradykinin | 1 | 2015 | 46 | 0.460 |
Why?
| | Oxidative Stress | 6 | 2025 | 1315 | 0.460 |
Why?
| | Models, Animal | 6 | 2019 | 384 | 0.460 |
Why?
| | Extracellular Traps | 1 | 2015 | 53 | 0.460 |
Why?
| | Immunologic Memory | 1 | 2017 | 370 | 0.450 |
Why?
| | Dehydration | 1 | 2015 | 52 | 0.450 |
Why?
| | Respiration | 1 | 2015 | 198 | 0.450 |
Why?
| | Primary Graft Dysfunction | 1 | 2014 | 30 | 0.450 |
Why?
| | Esophageal pH Monitoring | 1 | 2014 | 23 | 0.440 |
Why?
| | Adult | 32 | 2025 | 37724 | 0.430 |
Why?
| | Histones | 2 | 2016 | 636 | 0.430 |
Why?
| | Lipopolysaccharides | 5 | 2012 | 886 | 0.430 |
Why?
| | Breath Tests | 3 | 2016 | 87 | 0.430 |
Why?
| | Monocytes | 1 | 2016 | 563 | 0.420 |
Why?
| | Congresses as Topic | 4 | 2020 | 234 | 0.410 |
Why?
| | Scleroderma, Systemic | 1 | 2014 | 122 | 0.410 |
Why?
| | Dendritic Cells | 3 | 2016 | 484 | 0.400 |
Why?
| | Ileitis | 1 | 2013 | 32 | 0.400 |
Why?
| | Research Personnel | 1 | 2014 | 170 | 0.400 |
Why?
| | Permeability | 3 | 2022 | 162 | 0.400 |
Why?
| | Solvents | 1 | 2013 | 110 | 0.400 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2013 | 139 | 0.390 |
Why?
| | Mentors | 1 | 2014 | 199 | 0.390 |
Why?
| | Career Choice | 1 | 2014 | 216 | 0.390 |
Why?
| | Intestinal Diseases | 1 | 2012 | 42 | 0.380 |
Why?
| | Leukocyte Count | 5 | 2013 | 331 | 0.380 |
Why?
| | Graft Rejection | 2 | 2013 | 620 | 0.380 |
Why?
| | rac GTP-Binding Proteins | 1 | 2012 | 32 | 0.380 |
Why?
| | Injury Severity Score | 5 | 2017 | 524 | 0.380 |
Why?
| | Phagosomes | 1 | 2012 | 44 | 0.380 |
Why?
| | Fundoplication | 1 | 2012 | 53 | 0.370 |
Why?
| | Receptors, IgG | 1 | 2012 | 75 | 0.370 |
Why?
| | Staphylococcal Infections | 2 | 2013 | 401 | 0.370 |
Why?
| | Antibodies | 2 | 2013 | 412 | 0.370 |
Why?
| | Ischemia | 1 | 2015 | 407 | 0.370 |
Why?
| | Alanine Transaminase | 4 | 2021 | 157 | 0.360 |
Why?
| | Risk Factors | 12 | 2025 | 10368 | 0.360 |
Why?
| | Toll-Like Receptor 4 | 2 | 2010 | 273 | 0.360 |
Why?
| | Immunologic Factors | 2 | 2016 | 237 | 0.360 |
Why?
| | Prospective Studies | 9 | 2021 | 7595 | 0.350 |
Why?
| | Ligands | 2 | 2023 | 664 | 0.350 |
Why?
| | Logistic Models | 6 | 2019 | 2071 | 0.350 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 9 | 2018 | 851 | 0.350 |
Why?
| | Mice, Knockout | 7 | 2013 | 3009 | 0.340 |
Why?
| | Cell Separation | 1 | 2011 | 318 | 0.330 |
Why?
| | Down-Regulation | 1 | 2013 | 658 | 0.330 |
Why?
| | Cause of Death | 3 | 2019 | 429 | 0.330 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2010 | 139 | 0.330 |
Why?
| | Respiratory Function Tests | 3 | 2025 | 596 | 0.330 |
Why?
| | Toll-Like Receptor 2 | 1 | 2010 | 115 | 0.320 |
Why?
| | Actins | 1 | 2012 | 416 | 0.320 |
Why?
| | Protein Precursors | 2 | 2025 | 132 | 0.320 |
Why?
| | Immune Tolerance | 1 | 2012 | 362 | 0.310 |
Why?
| | Ileum | 2 | 2024 | 119 | 0.310 |
Why?
| | Environmental Pollutants | 1 | 2011 | 159 | 0.310 |
Why?
| | Receptors, Interleukin-8B | 2 | 2010 | 26 | 0.310 |
Why?
| | Interleukin-12 | 2 | 2013 | 121 | 0.310 |
Why?
| | Illinois | 4 | 2017 | 43 | 0.290 |
Why?
| | Occludin | 2 | 2021 | 12 | 0.290 |
Why?
| | Time Factors | 9 | 2019 | 6818 | 0.280 |
Why?
| | Cathelicidins | 2 | 2025 | 41 | 0.280 |
Why?
| | Aspartate Aminotransferases | 2 | 2021 | 90 | 0.280 |
Why?
| | Respiration, Artificial | 1 | 2012 | 643 | 0.270 |
Why?
| | Apoptosis | 6 | 2025 | 2554 | 0.270 |
Why?
| | Bronchoscopy | 3 | 2013 | 222 | 0.270 |
Why?
| | Plethysmography | 2 | 2019 | 106 | 0.270 |
Why?
| | Gastroenteritis | 1 | 2008 | 68 | 0.270 |
Why?
| | Smoking | 2 | 2013 | 1634 | 0.270 |
Why?
| | Young Adult | 9 | 2025 | 13163 | 0.270 |
Why?
| | Peroxidase | 3 | 2016 | 176 | 0.260 |
Why?
| | Peptides | 1 | 2012 | 982 | 0.250 |
Why?
| | Trachea | 1 | 2008 | 237 | 0.250 |
Why?
| | Statistics, Nonparametric | 5 | 2013 | 431 | 0.250 |
Why?
| | Cholera Toxin | 1 | 2025 | 32 | 0.240 |
Why?
| | Skin Ulcer | 2 | 2015 | 14 | 0.230 |
Why?
| | Bacteria | 3 | 2023 | 858 | 0.230 |
Why?
| | Haptoglobins | 1 | 2025 | 53 | 0.230 |
Why?
| | Bacteroidetes | 1 | 2024 | 24 | 0.230 |
Why?
| | Mitochondria, Liver | 1 | 2025 | 73 | 0.230 |
Why?
| | Retrospective Studies | 10 | 2023 | 15639 | 0.220 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2024 | 23 | 0.220 |
Why?
| | Survival Analysis | 3 | 2019 | 1321 | 0.220 |
Why?
| | Exhalation | 2 | 2016 | 39 | 0.220 |
Why?
| | ROC Curve | 5 | 2018 | 548 | 0.220 |
Why?
| | Burn Units | 2 | 2022 | 48 | 0.220 |
Why?
| | Aged, 80 and over | 5 | 2017 | 7607 | 0.220 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2025 | 151 | 0.220 |
Why?
| | Toxoplasmosis | 1 | 2024 | 39 | 0.210 |
Why?
| | Toxoplasma | 1 | 2024 | 41 | 0.210 |
Why?
| | Fatty Acids, Volatile | 1 | 2024 | 58 | 0.210 |
Why?
| | Hospital Mortality | 2 | 2019 | 903 | 0.210 |
Why?
| | Hepatocytes | 1 | 2025 | 220 | 0.210 |
Why?
| | Homeostasis | 2 | 2020 | 619 | 0.210 |
Why?
| | Multivariate Analysis | 3 | 2023 | 1521 | 0.210 |
Why?
| | Cohort Studies | 9 | 2019 | 5726 | 0.210 |
Why?
| | Hawaii | 1 | 2023 | 32 | 0.210 |
Why?
| | Zonula Occludens-1 Protein | 2 | 2013 | 16 | 0.200 |
Why?
| | alpha-Defensins | 1 | 2022 | 10 | 0.200 |
Why?
| | Whole-Body Irradiation | 2 | 2013 | 78 | 0.200 |
Why?
| | Body Surface Area | 1 | 2022 | 34 | 0.200 |
Why?
| | Phenotype | 4 | 2020 | 3202 | 0.200 |
Why?
| | Mitochondrial Proteins | 1 | 2025 | 256 | 0.190 |
Why?
| | Sex Characteristics | 3 | 2016 | 765 | 0.190 |
Why?
| | Veterans Health | 1 | 2024 | 185 | 0.190 |
Why?
| | Caspases | 1 | 2023 | 247 | 0.190 |
Why?
| | Veterans | 2 | 2024 | 1468 | 0.190 |
Why?
| | Fluorescent Antibody Technique | 3 | 2014 | 388 | 0.190 |
Why?
| | Critical Illness | 2 | 2018 | 808 | 0.190 |
Why?
| | Neurodegenerative Diseases | 1 | 2023 | 136 | 0.180 |
Why?
| | Interleukin-1beta | 3 | 2020 | 372 | 0.180 |
Why?
| | Malondialdehyde | 1 | 2021 | 29 | 0.180 |
Why?
| | Interleukins | 2 | 2014 | 251 | 0.180 |
Why?
| | Injections, Intraperitoneal | 2 | 2013 | 115 | 0.180 |
Why?
| | NF-kappa B | 1 | 2025 | 691 | 0.180 |
Why?
| | Colon | 1 | 2023 | 282 | 0.170 |
Why?
| | Hippocampus | 2 | 2025 | 895 | 0.170 |
Why?
| | Phosphorylation | 3 | 2016 | 1759 | 0.170 |
Why?
| | Frailty | 1 | 2024 | 170 | 0.170 |
Why?
| | Lipid Peroxidation | 1 | 2021 | 153 | 0.170 |
Why?
| | Analysis of Variance | 3 | 2014 | 1318 | 0.170 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 236 | 0.170 |
Why?
| | Streptococcus pneumoniae | 1 | 2022 | 169 | 0.170 |
Why?
| | Caspase 3 | 3 | 2023 | 246 | 0.170 |
Why?
| | Boston | 1 | 2020 | 91 | 0.160 |
Why?
| | Organ Specificity | 1 | 2020 | 304 | 0.160 |
Why?
| | Resistin | 1 | 2019 | 11 | 0.160 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2019 | 14 | 0.160 |
Why?
| | Ghrelin | 1 | 2019 | 36 | 0.160 |
Why?
| | Mannose-Binding Lectins | 1 | 2019 | 11 | 0.160 |
Why?
| | Cells, Cultured | 7 | 2016 | 4197 | 0.160 |
Why?
| | Metformin | 1 | 2023 | 330 | 0.160 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2019 | 86 | 0.160 |
Why?
| | Natural Killer T-Cells | 2 | 2010 | 67 | 0.160 |
Why?
| | Predictive Value of Tests | 3 | 2019 | 2032 | 0.160 |
Why?
| | Nanoparticles | 1 | 2025 | 484 | 0.160 |
Why?
| | Glutathione | 1 | 2021 | 358 | 0.150 |
Why?
| | Lectins, C-Type | 1 | 2019 | 67 | 0.150 |
Why?
| | Risk Assessment | 5 | 2019 | 3439 | 0.150 |
Why?
| | Air Pollutants | 1 | 2024 | 427 | 0.150 |
Why?
| | Fires | 1 | 2020 | 89 | 0.150 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2010 | 155 | 0.150 |
Why?
| | Life Style | 2 | 2014 | 488 | 0.150 |
Why?
| | Cell Count | 2 | 2016 | 323 | 0.150 |
Why?
| | Multiple Organ Failure | 2 | 2017 | 127 | 0.150 |
Why?
| | Administration, Oral | 2 | 2013 | 812 | 0.150 |
Why?
| | In Situ Nick-End Labeling | 1 | 2018 | 124 | 0.150 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 385 | 0.150 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2019 | 133 | 0.140 |
Why?
| | Prognosis | 3 | 2018 | 4026 | 0.140 |
Why?
| | Leptin | 1 | 2019 | 236 | 0.140 |
Why?
| | Toll-Like Receptors | 2 | 2009 | 185 | 0.140 |
Why?
| | Linear Models | 2 | 2017 | 846 | 0.140 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 976 | 0.140 |
Why?
| | Mental Health | 1 | 2024 | 725 | 0.140 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2020 | 549 | 0.140 |
Why?
| | Intensive Care Units | 4 | 2019 | 802 | 0.140 |
Why?
| | Needs Assessment | 1 | 2019 | 373 | 0.130 |
Why?
| | Receptors, Cell Surface | 1 | 2019 | 386 | 0.130 |
Why?
| | Tobacco Use | 1 | 2017 | 66 | 0.130 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3283 | 0.130 |
Why?
| | Transcriptome | 1 | 2023 | 972 | 0.130 |
Why?
| | United States | 10 | 2024 | 14742 | 0.130 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5125 | 0.130 |
Why?
| | Diet | 2 | 2014 | 1275 | 0.130 |
Why?
| | Monocyte Chemoattractant Proteins | 1 | 2015 | 8 | 0.120 |
Why?
| | Ovariectomy | 1 | 2016 | 152 | 0.120 |
Why?
| | Chemokine CXCL2 | 1 | 2015 | 43 | 0.120 |
Why?
| | Incidence | 3 | 2019 | 2808 | 0.120 |
Why?
| | Phylogeny | 1 | 2020 | 900 | 0.120 |
Why?
| | Acetylation | 1 | 2016 | 248 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2010 | 2052 | 0.120 |
Why?
| | Apicomplexa | 1 | 2015 | 2 | 0.120 |
Why?
| | Regression Analysis | 3 | 2013 | 1028 | 0.120 |
Why?
| | Polymerase Chain Reaction | 1 | 2018 | 1061 | 0.120 |
Why?
| | Imidazoles | 1 | 2016 | 239 | 0.120 |
Why?
| | Cognition | 1 | 2023 | 1169 | 0.110 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2015 | 28 | 0.110 |
Why?
| | Enzyme Inhibitors | 2 | 2016 | 839 | 0.110 |
Why?
| | Hematocrit | 1 | 2015 | 96 | 0.110 |
Why?
| | Killer Cells, Natural | 2 | 2008 | 445 | 0.110 |
Why?
| | Wasting Syndrome | 1 | 2014 | 13 | 0.110 |
Why?
| | Radiation Dosage | 1 | 2016 | 175 | 0.110 |
Why?
| | Insulin | 2 | 2019 | 2406 | 0.110 |
Why?
| | Gene Expression | 2 | 2018 | 1501 | 0.110 |
Why?
| | Fast Foods | 1 | 2014 | 17 | 0.110 |
Why?
| | Alcohol-Related Disorders | 1 | 2015 | 124 | 0.110 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2014 | 96 | 0.110 |
Why?
| | Leukocyte Disorders | 1 | 2014 | 10 | 0.110 |
Why?
| | Interleukin-23 | 1 | 2014 | 19 | 0.110 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 533 | 0.110 |
Why?
| | Respiratory Tract Diseases | 1 | 2016 | 187 | 0.110 |
Why?
| | Electric Stimulation Therapy | 1 | 2015 | 81 | 0.110 |
Why?
| | Caspase 8 | 1 | 2013 | 48 | 0.110 |
Why?
| | Sex Factors | 4 | 2019 | 2073 | 0.110 |
Why?
| | Viruses | 1 | 2015 | 113 | 0.110 |
Why?
| | Health | 1 | 2014 | 84 | 0.110 |
Why?
| | Lung Injury | 1 | 2016 | 218 | 0.110 |
Why?
| | Fungi | 1 | 2015 | 148 | 0.110 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2014 | 56 | 0.110 |
Why?
| | Immune System Diseases | 1 | 2014 | 39 | 0.110 |
Why?
| | Faculty | 1 | 2014 | 145 | 0.100 |
Why?
| | Lymphocyte Subsets | 1 | 2013 | 87 | 0.100 |
Why?
| | Myosin Light Chains | 1 | 2013 | 26 | 0.100 |
Why?
| | Th17 Cells | 1 | 2014 | 109 | 0.100 |
Why?
| | Employment | 1 | 2014 | 178 | 0.100 |
Why?
| | Creatinine | 1 | 2015 | 499 | 0.100 |
Why?
| | Pyridines | 1 | 2016 | 506 | 0.100 |
Why?
| | Adipose Tissue | 2 | 2015 | 630 | 0.100 |
Why?
| | Immunoassay | 1 | 2013 | 113 | 0.100 |
Why?
| | Calcitonin | 1 | 2012 | 27 | 0.100 |
Why?
| | Bacterial Load | 1 | 2012 | 68 | 0.100 |
Why?
| | Bile Acids and Salts | 1 | 2014 | 200 | 0.100 |
Why?
| | Vinculin | 1 | 2012 | 10 | 0.100 |
Why?
| | Syndrome | 1 | 2013 | 357 | 0.100 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 253 | 0.100 |
Why?
| | Paxillin | 1 | 2012 | 10 | 0.100 |
Why?
| | Receptors, Interleukin-4 | 1 | 2011 | 16 | 0.090 |
Why?
| | Anti-Infective Agents | 1 | 2015 | 254 | 0.090 |
Why?
| | Decidua | 1 | 1992 | 24 | 0.090 |
Why?
| | Social Class | 1 | 2014 | 281 | 0.090 |
Why?
| | Receptors, Interleukin-2 | 1 | 1992 | 66 | 0.090 |
Why?
| | Chorionic Villi | 1 | 1992 | 25 | 0.090 |
Why?
| | Focal Adhesions | 1 | 2012 | 44 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2016 | 1987 | 0.090 |
Why?
| | Pregnancy | 2 | 2023 | 6743 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2023 | 1904 | 0.090 |
Why?
| | Ubiquitin | 1 | 2012 | 66 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 81 | 0.090 |
Why?
| | rho GTP-Binding Proteins | 1 | 2012 | 60 | 0.090 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2011 | 173 | 0.090 |
Why?
| | Polymerization | 1 | 2012 | 126 | 0.090 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 284 | 0.090 |
Why?
| | Blood Glucose | 2 | 2019 | 2182 | 0.090 |
Why?
| | Vehicle Emissions | 1 | 2011 | 67 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2012 | 119 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.090 |
Why?
| | Phagocytes | 2 | 2009 | 100 | 0.090 |
Why?
| | Pulmonary Alveoli | 1 | 2013 | 405 | 0.090 |
Why?
| | Cytoskeleton | 1 | 2012 | 188 | 0.090 |
Why?
| | Tissue Engineering | 1 | 2015 | 418 | 0.090 |
Why?
| | Nitric Oxide | 1 | 2016 | 915 | 0.090 |
Why?
| | Bone Marrow Cells | 1 | 2011 | 316 | 0.090 |
Why?
| | Edema | 1 | 2011 | 130 | 0.080 |
Why?
| | Specimen Handling | 1 | 2012 | 181 | 0.080 |
Why?
| | Writing | 1 | 2012 | 94 | 0.080 |
Why?
| | Body Composition | 1 | 2014 | 678 | 0.080 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1734 | 0.080 |
Why?
| | Dermatitis | 1 | 2010 | 20 | 0.080 |
Why?
| | Equipment Design | 1 | 2012 | 522 | 0.080 |
Why?
| | Ozone | 1 | 2011 | 131 | 0.080 |
Why?
| | Bacteremia | 1 | 2012 | 211 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2234 | 0.080 |
Why?
| | DNA | 2 | 2015 | 1459 | 0.080 |
Why?
| | Trophoblasts | 1 | 1992 | 199 | 0.080 |
Why?
| | Adiposity | 1 | 2014 | 518 | 0.080 |
Why?
| | Respiration Disorders | 1 | 2010 | 77 | 0.080 |
Why?
| | Adolescent | 5 | 2017 | 21499 | 0.080 |
Why?
| | Cystic Fibrosis | 1 | 2019 | 1104 | 0.080 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2011 | 228 | 0.080 |
Why?
| | Interleukin-18 | 1 | 2010 | 237 | 0.080 |
Why?
| | Odds Ratio | 1 | 2012 | 1067 | 0.080 |
Why?
| | Mass Screening | 2 | 2015 | 1268 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2836 | 0.080 |
Why?
| | Histiocytes | 1 | 2008 | 7 | 0.070 |
Why?
| | Escherichia coli K12 | 1 | 2008 | 7 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2012 | 288 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 892 | 0.070 |
Why?
| | Membrane Fluidity | 1 | 2008 | 11 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2014 | 648 | 0.070 |
Why?
| | Hypersensitivity, Delayed | 1 | 2008 | 28 | 0.070 |
Why?
| | Membrane Microdomains | 1 | 2008 | 31 | 0.070 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 15 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 916 | 0.070 |
Why?
| | Shock | 1 | 2009 | 95 | 0.070 |
Why?
| | Interleukin-2 | 1 | 2009 | 455 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 86 | 0.070 |
Why?
| | Opportunistic Infections | 1 | 2008 | 45 | 0.070 |
Why?
| | Manometry | 3 | 2013 | 95 | 0.070 |
Why?
| | Comorbidity | 3 | 2019 | 1624 | 0.070 |
Why?
| | Cell Survival | 2 | 2025 | 1119 | 0.070 |
Why?
| | Capillary Permeability | 1 | 2008 | 145 | 0.070 |
Why?
| | Testis | 1 | 2008 | 151 | 0.070 |
Why?
| | Intubation, Gastrointestinal | 1 | 2008 | 78 | 0.070 |
Why?
| | Pediatric Obesity | 1 | 2014 | 590 | 0.070 |
Why?
| | Protein Kinases | 1 | 2009 | 319 | 0.070 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 452 | 0.070 |
Why?
| | Survival Rate | 1 | 2012 | 1970 | 0.070 |
Why?
| | Mast Cells | 1 | 2008 | 147 | 0.070 |
Why?
| | Neovascularization, Physiologic | 1 | 2008 | 178 | 0.070 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2008 | 197 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 3 | 2013 | 564 | 0.060 |
Why?
| | Gonadal Steroid Hormones | 1 | 2008 | 140 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2008 | 226 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2008 | 1089 | 0.060 |
Why?
| | Reproduction | 1 | 2008 | 204 | 0.060 |
Why?
| | Interleukin-1 | 1 | 2010 | 964 | 0.060 |
Why?
| | Cell Line | 1 | 2012 | 2841 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2009 | 790 | 0.060 |
Why?
| | Cell Communication | 1 | 2008 | 315 | 0.060 |
Why?
| | Asthma | 2 | 2016 | 2293 | 0.060 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2013 | 653 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2012 | 10800 | 0.060 |
Why?
| | Eosinophils | 1 | 2008 | 332 | 0.060 |
Why?
| | Reference Values | 2 | 2019 | 818 | 0.060 |
Why?
| | Research Design | 1 | 2012 | 1128 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1946 | 0.060 |
Why?
| | Serum Amyloid A Protein | 1 | 2025 | 32 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 1009 | 0.060 |
Why?
| | Barrett Esophagus | 3 | 2012 | 149 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 658 | 0.060 |
Why?
| | Neoplasms | 2 | 2016 | 2661 | 0.060 |
Why?
| | Lomustine | 1 | 2024 | 14 | 0.060 |
Why?
| | Hemorrhage | 1 | 2009 | 723 | 0.060 |
Why?
| | Antibodies, Protozoan | 1 | 2024 | 35 | 0.050 |
Why?
| | Anti-Inflammatory Agents | 1 | 2008 | 498 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1805 | 0.050 |
Why?
| | Antioxidants | 1 | 2008 | 586 | 0.050 |
Why?
| | Gene Silencing | 1 | 2025 | 195 | 0.050 |
Why?
| | Inflammasomes | 1 | 2025 | 128 | 0.050 |
Why?
| | Metals, Heavy | 1 | 2024 | 32 | 0.050 |
Why?
| | Pesticides | 1 | 2024 | 61 | 0.050 |
Why?
| | Case-Control Studies | 4 | 2015 | 3546 | 0.050 |
Why?
| | Caspase 9 | 1 | 2023 | 57 | 0.050 |
Why?
| | Europe | 2 | 2014 | 414 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2025 | 206 | 0.050 |
Why?
| | Surveys and Questionnaires | 4 | 2019 | 5769 | 0.050 |
Why?
| | Prednisone | 1 | 2024 | 243 | 0.050 |
Why?
| | Exercise | 1 | 2014 | 2045 | 0.050 |
Why?
| | Microglia | 1 | 2025 | 251 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2008 | 779 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 288 | 0.050 |
Why?
| | DNA Repair | 1 | 1984 | 231 | 0.050 |
Why?
| | Virulence | 1 | 2023 | 265 | 0.050 |
Why?
| | Lymphocytes | 1 | 1984 | 395 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2025 | 622 | 0.050 |
Why?
| | Energy Metabolism | 1 | 2008 | 920 | 0.050 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2023 | 197 | 0.050 |
Why?
| | Hernia, Hiatal | 2 | 2012 | 35 | 0.050 |
Why?
| | Blood Alcohol Content | 1 | 2021 | 5 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2023 | 316 | 0.040 |
Why?
| | Colorado | 2 | 2024 | 4527 | 0.040 |
Why?
| | Ventricular Remodeling | 1 | 2023 | 262 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2023 | 283 | 0.040 |
Why?
| | Air Pollution | 1 | 2024 | 315 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2024 | 676 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2024 | 886 | 0.040 |
Why?
| | Firefighters | 1 | 2020 | 43 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2024 | 577 | 0.040 |
Why?
| | Chronic Disease | 2 | 2015 | 1788 | 0.040 |
Why?
| | Patient Care Team | 1 | 2024 | 629 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2024 | 523 | 0.040 |
Why?
| | Half-Life | 1 | 2018 | 165 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2013 | 544 | 0.040 |
Why?
| | California | 1 | 2019 | 424 | 0.030 |
Why?
| | Reference Standards | 1 | 2018 | 186 | 0.030 |
Why?
| | Age of Onset | 1 | 2019 | 519 | 0.030 |
Why?
| | Disease Progression | 2 | 2015 | 2752 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 104 | 0.030 |
Why?
| | Forkhead Box Protein O3 | 1 | 2016 | 17 | 0.030 |
Why?
| | Dried Blood Spot Testing | 1 | 2017 | 103 | 0.030 |
Why?
| | Shock, Septic | 1 | 2019 | 221 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2017 | 132 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2019 | 504 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2023 | 1774 | 0.030 |
Why?
| | Propensity Score | 1 | 2017 | 290 | 0.030 |
Why?
| | Bronchoalveolar Lavage | 1 | 2015 | 93 | 0.030 |
Why?
| | Rats | 3 | 2014 | 5639 | 0.030 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2016 | 368 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 826 | 0.030 |
Why?
| | Endocrine System | 1 | 2014 | 20 | 0.030 |
Why?
| | Administration, Topical | 1 | 2015 | 149 | 0.030 |
Why?
| | Psoriasis | 1 | 2015 | 102 | 0.030 |
Why?
| | Hemostasis | 1 | 2014 | 82 | 0.030 |
Why?
| | Critical Care | 1 | 2019 | 584 | 0.030 |
Why?
| | Prevalence | 2 | 2011 | 2715 | 0.030 |
Why?
| | Anthropometry | 1 | 2014 | 213 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2014 | 195 | 0.030 |
Why?
| | Pneumonia, Aspiration | 1 | 2013 | 18 | 0.030 |
Why?
| | Canada | 1 | 2015 | 421 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2016 | 412 | 0.030 |
Why?
| | Culture | 1 | 2014 | 127 | 0.030 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 43 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 315 | 0.030 |
Why?
| | Virus Diseases | 1 | 2015 | 214 | 0.030 |
Why?
| | Forecasting | 1 | 2015 | 387 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5436 | 0.020 |
Why?
| | Acute-Phase Proteins | 1 | 2012 | 67 | 0.020 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2012 | 39 | 0.020 |
Why?
| | Disease Management | 1 | 2016 | 627 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2608 | 0.020 |
Why?
| | Health Surveys | 1 | 2014 | 517 | 0.020 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 1 | 2012 | 6 | 0.020 |
Why?
| | Societies, Medical | 1 | 2016 | 822 | 0.020 |
Why?
| | Barium Sulfate | 1 | 2012 | 15 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1484 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 679 | 0.020 |
Why?
| | Fluorescence | 1 | 2012 | 160 | 0.020 |
Why?
| | Gastric Emptying | 1 | 2012 | 38 | 0.020 |
Why?
| | Monitoring, Ambulatory | 1 | 2012 | 87 | 0.020 |
Why?
| | Radiopharmaceuticals | 1 | 2012 | 178 | 0.020 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1992 | 137 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 1992 | 143 | 0.020 |
Why?
| | Esophagitis | 1 | 2011 | 67 | 0.020 |
Why?
| | DNA Fragmentation | 1 | 2010 | 41 | 0.020 |
Why?
| | bcl-X Protein | 1 | 2010 | 43 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2010 | 56 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 38 | 0.020 |
Why?
| | Pneumonia, Viral | 1 | 2015 | 368 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2018 | 871 | 0.020 |
Why?
| | Morbidity | 1 | 2011 | 324 | 0.020 |
Why?
| | Abortion, Induced | 1 | 1992 | 103 | 0.020 |
Why?
| | Chromatography, Gel | 1 | 2009 | 127 | 0.020 |
Why?
| | Antigens, CD1d | 1 | 2009 | 68 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 500 | 0.020 |
Why?
| | Child, Preschool | 2 | 2014 | 11080 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 832 | 0.020 |
Why?
| | Reoperation | 1 | 2012 | 583 | 0.020 |
Why?
| | Esophagus | 1 | 2011 | 255 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1992 | 387 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 969 | 0.020 |
Why?
| | Contrast Media | 1 | 2012 | 462 | 0.020 |
Why?
| | Nursing Assessment | 1 | 2009 | 57 | 0.020 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2009 | 165 | 0.020 |
Why?
| | tert-Butyl Alcohol | 1 | 2008 | 1 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 1042 | 0.020 |
Why?
| | Alcohol Dehydrogenase | 1 | 2008 | 16 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 786 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 1991 | 480 | 0.020 |
Why?
| | Oligopeptides | 1 | 2010 | 272 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2012 | 769 | 0.020 |
Why?
| | Antibodies, Neutralizing | 1 | 2010 | 285 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2008 | 226 | 0.020 |
Why?
| | Collagen | 1 | 2009 | 446 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 278 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2010 | 1150 | 0.020 |
Why?
| | Risk-Taking | 1 | 2009 | 349 | 0.020 |
Why?
| | Body Mass Index | 1 | 2014 | 2373 | 0.020 |
Why?
| | Fibroblasts | 1 | 1991 | 993 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2008 | 617 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2486 | 0.010 |
Why?
| | Pyrazoles | 1 | 2008 | 423 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1998 | 0.010 |
Why?
| | Testosterone | 1 | 2008 | 401 | 0.010 |
Why?
| | Hydroxyurea | 1 | 1984 | 35 | 0.010 |
Why?
| | Child | 2 | 2014 | 21999 | 0.010 |
Why?
| | Brain | 1 | 2015 | 2675 | 0.010 |
Why?
| | Quality of Life | 1 | 2015 | 2885 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 1984 | 390 | 0.010 |
Why?
| | Registries | 1 | 2008 | 2016 | 0.010 |
Why?
| | Bleomycin | 1 | 1991 | 247 | 0.000 |
Why?
| | Oxygen | 1 | 1991 | 935 | 0.000 |
Why?
| | RNA, Messenger | 1 | 1991 | 2839 | 0.000 |
Why?
|
|
Kovacs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|